autologous T-cell therapy (Roger Williams Medical Center)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameautologous T-cell therapy (Roger Williams Medical Center)
Drug Alias Namechimeric anti-PSMA antibody-TCR gene therapy(Roger Williams)anti-PSMA designer T cells (Roger Williams)retrovirus-based ex vivo gene therapy (Roger Williams Medical Center)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionProstate-Specific Membrane Antigen modulatorsT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3Prostate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRoger Williams Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRoger Williams Medical Center
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A